DW91170
/ Dong Wha
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 14, 2023
DW91170: A novel potent EZH1/2 dual inhibitor for lymphoma treatment
(AACR 2023)
- "In order to verify the potential of DW91170 in R/R-lymphoma patients, the anti-cancer effect was evaluated in Rituximab-resistant cell line and R/R-DLBCL patient-derived PDX model. Taken together, we demonstrated that DW91170, a dual epigenetic regulator of EZH1 and EZH2, showed great anti-tumor activities in various lymphoma cell lines and animal models such as CDX and PDX. We are currently trying to expand indication into solid tumor to find a targetable population in clinical trials."
Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • EZH2
1 to 1
Of
1
Go to page
1